Background and Objectives: The impact on long-term adverse cardiac events of troponin T （TnT） or creatine kinase-MB （CK-MB） release after percutaneous transluminal coronary angioplasty （PTCA） is not well defined. The purpose of the study is
to evaluate the effect of elevated TnT or CK-MB on the late major adverse cardiac events [MACE；Q wave myocardial infarction （MI）, revascularization, or cardiac death].
Subjects and Methods: Study population were 207 consecutive patients （M：F＝148：59, mean 60.8±9.2 years） who underwent PTCA. Patients with acute MI, unstable angina with abnormal levels of TnT or CK-MB, or newly developed Q MI after PTCA were
excluded. Cardiac enzyme levels were measured before and 8, 24 hours after PTCA for CK-MB, and before and 16 hours after PTCA for TnT. Group Ⅰ （n＝181, 87.4%） had normal levels of both after PTCA. Group Ⅱ （n＝26, 12.6%） had abnormal levels of
CK-MB （≥16 μ/ℓ） and/or TnT （≥0.2 ng/㎖）. 1-year follow-up was available in 201 （97.1%） patients.
Results: Incidence of non-Q MI after PTCA was 26/207 （12.6%）. Major complications such as acute coronary occlusion, side branch occlusion, and major dissection were significantly associated with elevation of TnT or CK-MB after PTCA （p＝0.01）.
However, elevation of CK-MB or TnT was not significantly associated with late MACE by Kaplan-Meier survival curve （p＝0.46）. During 1-year follow-up, event free rate of group Ⅰ and Ⅱ were 76.6% and 69.2%, respectively.
Conclusion: Acute coronary occlusion, side branch occlusion, or major dissection can increase the level of TnT or CK-MB after PTCA. But, elevation of CK-MB or TnT after PTCA dose not significantly influence on late MACE.
Angioplasty, transluminal, percutaneous coronary; Creatine kinase; Myocardial infarction; Troponin T;
|